Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008151 | 0.85 | P2RX7 (0.46) | EHMT2BRD4ACHEP2RX7MEN1 | |
| SCHEMBL1189963 | 0.85 | P2RX7 (0.46) | EHMT2BRD4ACHEP2RX7MEN1 | |
| SCHEMBL1008150 | 0.85 | P2RX7 (0.46) | EHMT2BRD4ACHEP2RX7MEN1 | |
| SCHEMBL2118646 | 0.81 | CHRM2 (0.45) | EHMT2P2RX7MEN1KMT2AHCRTR1 | |
| SCHEMBL7407552 | 0.80 | HCRTR2 (0.50) | EHMT2BRD4ACHEMEN1KMT2A | |
| SCHEMBL2265479 | 0.80 | HCRTR2 (0.50) | EHMT2BRD4ACHEMEN1KMT2A | |
| SCHEMBL27091858 | 0.77 | HCRTR1 (0.58) | P2RX7HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2341733 | 0.77 | HCRTR1 (0.42) | EHMT2BRD4MEN1KMT2AHCRTR1 | |
| SCHEMBL21538655 | 0.76 | LMNA (0.50) | EHMT2BRD4ACHEMEN1KMT2A | |
| SCHEMBL2338116 | 0.76 | HCRTR1 (0.53) | ACHEMEN1KMT2AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2414349-A1 | 3-Ý1,4¨OXAZEPANE-4-PYRIMIDONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110207715-A1 | Disubstituted Azepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207715-A1 | Disubstituted Azepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | EHMT2 2432/4885BRD4 1658/4885ACHE 918/4885 |
| US-20240199584-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | EHMT2 2202/4885BRD4 443/4885ACHE 4848/4885 |
| US-20110207715-A1 | Disubstituted Azepan Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | EHMT2 1137/4885BRD4 1727/4885ACHE 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.